NOD/ShiJcl

Animals/Diabetes Models/

NOD/ShiJcl

Ordering name: NOD/ShiJcl
Nomenclature: NOD/ShiJcl
Availability: Live colony

Origin

Dr. Yoshihiro Tochino and Dr. Susumu Makino identified female mice that exhibited polyuria and were highly positive for urinary glucose among cataract mice (CT strain) derived from ICR-JCL mice. Because the symptoms of these mice resembled human type 1 diabetes mellitus (insulin-dependent diabetes mellitus), the strain was named NOD (Non-Obese Diabetes). In 1984, a contract was concluded among Shionogi Pharmaceutical Co., Ltd.; the Central Institute for Experimental Animals (CIEA); and CLEA Japan, Inc. Production of the strain was begun by the CIEA, and the supply of the strain was provided by our company.
Since January 2008, based on a contract between Shionogi Pharmaceutical Co., Ltd., and CLEA Japan, Inc., this strain has been produced as NOD/ShiJcl for sale by our company.
“Shi” denotes the origin of the strain from Shionogi Pharmaceutical Col., Ltd.

Characteristics

Because of the destruction of β cells by lymphocyte infiltration in Langerhans islets in the pancreas, mice of this strain spontaneously develop insulin-dependent diabetes mellitus. An obvious sex-related difference exists in the incidence of diabetes, with an actual incidence of 70% ? 80% for females and 20% to 30% for males when the cumulative total of cases up to 30 weeks after birth is considered. Langerhans islet inflammation involves a polygenic model that is genetically controlled by the presence of major histocompatibility (MHC) antigen and a number of related genes. Because diabetes does not occur in NOD mouse homozygotes in which the nu gene has been introduced, this condition is speculated to be a T cell-dependent autoimmune response.

Use

  • Elucidation of the etiologic mechanisms of type 1 diabetes mellitus
  • Research and development of gene therapy

Background Data (weight, blood property, blood biochemistry, organ weight)

Promotion Info.

 

Products